Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

MARÍA DE LA PAZ SARASOLA; MONICA TAQUEZ DELGADO; MELISA NICOUD; VANINA A MEDINA

Pharmacological Research and Perspectives

Wiley

Año: 2021

Cancer is the second leading cause of death globally and its incidence and mortalityare rapidly increasing worldwide. The dynamic interaction of immune cells and tumorcells determines the clinical outcome of cancer. Immunotherapy comes to the forefrontof cancer treatments, resulting in impressive and durable responses but only ina fraction of patients. Thus, understanding the characteristics and profiles of immunecells in the tumor microenvironment (TME) is a necessary step to move forward in thedesign of new immunomodulatory strategies that can boost the immune system tofight cancer. Histamine produces a complex and fine-tunedregulation of the phenotypeand functions of the different immune cells, participating in multiple regulatoryresponses of the innate and adaptive immunity. Considering the important actionsof histamine-producingimmune cells in the TME, in this review we first address themost important immunomodulatory roles of histamine and histamine receptors in thecontext of cancer development and progression. In addition, this review highlightsthe current progress and foundational developments in the field of cancer immunotherapyin combination with histamine and pharmacological compounds targetinghistamine receptors.